- Home
- GLO vs HRTX Comparison
GLO vs HRTX Comparison
Compare GLO & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLO | HRTX |
|---|---|---|
| Founded | N/A | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.7M | 265.9M |
| IPO Year | 2006 | 2007 |
Fundamental Metrics
Financial Performance| Metric | GLO | HRTX |
|---|---|---|
| Price | $6.07 | $1.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 186.3K | ★ 1.5M |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $154,904,000.00 |
| Revenue This Year | N/A | $13.08 |
| Revenue Next Year | N/A | $20.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.36 |
| 52 Week Low | $4.32 | $1.00 |
| 52 Week High | $6.09 | $2.68 |
Technical Indicators
Market Signals| Indicator | GLO | HRTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.80 | 44.49 |
| Support Level | $5.93 | $1.07 |
| Resistance Level | $6.09 | $1.37 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 13.33 | 46.43 |
Price Performance
Historical ComparisonAbout GLO Clough Global Opportunities Fund
Clough Global Opportunities Fund is a closed-end management investment company based in the United States. Its investment objective is to provide a high level of total return by investing in equity securities of companies of any market capitalization and equity-related securities, including equity swaps and call options, as well as fixed-income securities, including both corporate and sovereign debt, in both U.S. and non-U.S. markets.
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.